TGF-beta antibodies: a novel treatment for pulmonary fibrosis?

Laurent, G J; Coker, R K; McAnulty, R J
October 1993
Thorax;Oct1993, Vol. 48 Issue 10, p953
Academic Journal
No abstract available.


Related Articles

  • Optimal treatment for idiopathic pulmonary fibrosis. Maher, T. M.; Wells, A. U.; Williams, T. J.; Wilson, J. W. // Thorax;Dec2008, Vol. 63 Issue 12, p1120 

    A letter to the editor is presented in response to the review of novel treatment and lung transplantation in pulmonary fibrosis by Williams and Wilson.

  • Characterization of the innate immune response to chronic aspiration in a novel rodent model. Appel III, James Z.; Lee, Sean M.; Hartwig, Matthew G.; Bin Li; Chong-Chao Hsieh; Cantu III, Edward; Yonghan Yoon; Lin, Shu S.; Parker, William; Davis, R. Duane // Respiratory Research;2007, Vol. 8, p87 

    Background: Although chronic aspiration has been associated with several pulmonary diseases, the inflammatory response has not been characterized. A novel rodent model of chronic aspiration was therefore developed in order to investigate the resulting innate immune response in the lung. Methods:...

  • Evidence that TGF-β should be a therapeutic target in diabetic nephropathy. Border, Wayne A.; Noble, Nancy A. // Kidney International;Oct1998, Vol. 54 Issue 4, p1390 

    Editorial. Comments on the importance of transforming growth factor-beta (TGF-beta) as treatment for diabetic nephropathy. Features of fibrosis in the diabetic kidney; Potentials of TGF-beta fibrogen; Evidence in implicating TGF-beta overexpression in the pathogenesis of diabetic nephropathy.

  • Possible New Approach for IPF Treatment.  // AARC Times;Jul2015, Vol. 39 Issue 7, p51 

    This article reports that investigators at the Saban Research Institute at Children's Hospital Los Angeles have identified a possible new approach for the treatment of patients with idiopathic pulmonary fibrosis. Topics discussed include the essential role which TGF-beta signaling plays in lung...

  • Pin1 regulates TGF-beta1 production by activated human and murine eosinophils and contributes to allergic lung fibrosis. Zhong-Jian Shen; Esnault, Stephane; Rosenthal, Louis A.; Szakaly, Renee J.; Sorkness, Ronald L.; Westmark, Pamela R.; Sandor, Matyas; Malter, James S.; Shen, Zhong-Jian // Journal of Clinical Investigation;Feb2008, Vol. 118 Issue 2, p479 

    Eosinophilic inflammation is a cornerstone of chronic asthma that often culminates in subepithelial fibrosis with variable airway obstruction. Pulmonary eosinophils (Eos) are a predominant source of TGF-beta1, which drives fibroblast proliferation and extracellular matrix deposition. We...

  • IL-7 inhibits fibroblast TGF-beta production and signaling in pulmonary fibrosis. Huang, Min; Sharma, Sherven; Zhu, Li X; Keane, Michael P; Luo, Jie; Zhang, Ling; Burdick, Marie D; Lin, Ying Q; Dohadwala, Mariam; Gardner, Brian; Batra, Raj K; Strieter, Robert M; Dubinett, Steven M // Journal of Clinical Investigation;4/1/2002, Vol. 109 Issue 7, p931 

    Based on studies by our group and others, we hypothesized that IL-7 may possess antifibrotic activities in an IFN-gamma-dependent and independent manner. Here, we have evaluated the antifibrotic therapeutic potential of IL-7 in both in vitro and in vivo pulmonary fibrosis models. IL-7 inhibited...

  • Transforming Growth Factor-Beta Superfamily Members in the Pathogenesis of Pulmonary Arterial Hypertension. Jerkić, Mirjana // Scripta Medica;2012, Vol. 43 Issue 2, p106 

    Pulmonary arterial hypertension (PAH) is a devastating and rapidly progressing disease that induces substantial pulmonary vascular remodeling. The pathologic changes especially in pulmonary microvasculature result in progressive increases in the mean pulmonary artery pressure and pulmonary...

  • Asiatic Acid Inhibits Liver Fibrosis by Blocking TGF-beta/Smad Signaling In Vivo and In Vitro. Li-xia Tang; Rui-hua He; Guang Yang; Jia-ju Tan; Li Zhou; Xiao-ming Meng; Xiao Ru Huang; Hui Yao Lan // PLoS ONE;Feb2012, Vol. 7 Issue 2, p1 

    Liver fibrosis is a major cause of liver failure, but treatment remains ineffective. In the present study, we investigated the mechanisms and anti-hepatofibrotic activities of asiatic acid (AA) in a rat model of liver fibrosis induced by carbon tetrachloride (CCl4) and in vitro in...

  • HIPK2 is a new drug target for anti-fibrosis therapy in kidney disease. Nugent, Melinda M.; Kyung Lee; John Cijiang He // Frontiers in Physiology;Apr2015, Vol. 6, p1 

    In vitro and animal studies continue to elucidate the mechanisms of fibrosis and have led to advancements in treatment for idiopathic pulmonary fibrosis and cirrhosis, but the search for treatments for renal fibrosis has been more disappointing. Here, we will discuss...

  • Acute Exacerbations in Idiopathic Pulmonary Fibrosis. Crowley, Searnus P.; Kelly, Peter; Egan, Jim J. // Annals of Internal Medicine;2/7/2006, Vol. 144 Issue 3, p218 

    A letter to the editor is presented commenting on the treatment of patients with idiopathic pulmonary fibrosis.


Read the Article


Sign out of this library

Other Topics